Seven pharma businesses are in the top 100 for innovation, according to Thomson Reuters. The seven are Johnson & Johnson, Novartis, Roche, Abbott, Bayer, Bristol-Myers Squibb and Boehringer Ingelheim.
The business intelligence company’s report says: “As genomics drives the era of precision medicine and more and more therapies are being developed to specifically target mutant cells, especially as witnessed in oncology, in addition to the use of biologics in developing new treatments, the pharmaceutical space is experiencing a pseudo rebirth, despite the decline of the Blockbuster drug era.”
Thomson Reuters cited the lack of UK pharma presence on the list as being due to a lack of investment in R&D. The UK’s environment is improving, however, and initiatives such as the patent box will help. This will take at least a couple of years to feed through to results, though.